On November 16, 2026, CG Oncology announced that its experimental oncolytic immunotherapy cretostimogene grenadenorepvec reduced the risk of tumor recurrence by 68% in a Phase 3 trial of 367 patients with intermediate-risk non-muscle-invasive bladder cancer. Shares of CG Oncology jumped over 30% in premarket trading following the news. The company expects to present additional trial data in December 2026 and submit an FDA application before the end of March 2027.
Phase 3 trial efficacy and safety results
- ▪CG Oncology said Cretostimogene grenadenorepvec was generally well tolerated in the Phase 3 trial, with safety results consistent with those reported in previous studies of the immunotherapy
- ▪In a randomized Phase 3 trial of 367 patients with intermediate-risk non-muscle-invasive bladder cancer following complete tumor resection, CG Oncology's cretostimogene grenadenorepvec reduced the risk of tumor recurrence by 68% compared to current medical practice
Market reaction and commercial outlook
- ▪Following the announcement of positive Phase 3 trial results on November 16, 2026, CG Oncology shares rose more than 30% to $98 in premarket trading
- ▪Phase 3 trial success in intermediate-risk non-muscle-invasive bladder cancer potentially expands the commercial market for CG Oncology's cretostimogene immunotherapy asset significantly
Overview and impact of non-muscle-invasive bladder cancer
- ▪Intermediate-risk non-muscle-invasive bladder cancer is typically removed through minimally invasive surgery, but recurrent tumors over time can compromise bladder function and allow the cancer to grow
- ▪Standard monitoring for intermediate-risk non-muscle-invasive bladder cancer requires patient evaluations every three months, with repeat surgical procedures performed whenever the cancer recurs
- ▪Approximately 75% of newly diagnosed bladder cancers are non-muscle-invasive, a form of the disease that can recur and potentially grow into the bladder muscle
Story comments
Loading comments…